Medical aesthetics company that produced injectable implant products used in minimally invasive soft tissue augmentation procedures
BioForm Medical was a medical aesthetics company focused on developing and commercializing products used by physicians to enhance a patient’s appearance. The company was a leader in the dermal filler market in the United States and Europe with its flagship product, RADIESSE®, for which it obtained FDA approval for the correction of moderate to severe folds and wrinkles in 2005. The company’s pipeline also included a number of additional aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. The company completed its initial public offering in 2007.
BioForm Medical was a medical aesthetics company focused on developing and commercializing products used by physicians to enhance a patient’s appearance. The company was a leader in the dermal filler market in the United States and Europe with its flagship product, RADIESSE®, for which it obtained FDA approval for the correction of moderate to severe folds and wrinkles in 2005. The company’s pipeline also included a number of additional aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. The company completed its initial public offering in 2007.
Employees: 501-1000
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | EW Healthc... | ewhealthca... |
Mentions in press and media 4
| Date | Title | Description |
| 02.07.2020 | MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings | Jul 02 2020 Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management. EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkin... |
| 28.05.2011 | Uroplasty sets its sights on SUI market vacated by Bard | Uroplasty Inc. (NSDQ:UPI) is hoping to corner a big piece of the $20 million market for bulking agents used to treat stress unrinary incontinence now that C.R. Bard (NYSE:BCR) is no longer a player in the space. "It’s not a particularl... |
| 17.05.2011 | Essex Woodlands PIPE Helped Power Orthovita to $316M Stryker Deal | May 17 2011 MALVERN, Pennsylvania— Stryker Corp. is buying publicly held orthobiologics company Orthovita Inc. in a $316 million cash deal that will provide another exit for Essex Woodlands Health Ventures, which led a $32.5 million PIPE f... |
| 04.01.2010 | Merz to Acquire BioForm Medical | Jan 04 2010 FRANKFURT, Germany and SAN MATEO, California –– Merz Pharma Group (“Merz”), a privately-held company based in Frankfurt am Main, Germany, and BioForm Medical, Inc. (Nasdaq: BFRM) today announced that the Board of Directors of B... |